SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:7ffe7333-9451-492e-9bd8-32d7c187edaa"
 

Search: onr:"swepub:oai:lup.lub.lu.se:7ffe7333-9451-492e-9bd8-32d7c187edaa" > Functional Assessme...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry

Greenbaum, Larry A. (author)
Children's Healthcare of Atlanta,Emory University
Licht, Christoph (author)
Hospital for Sick Children, Toronto
Nikolaou, Vasileios (author)
Parexel International
show more...
Al-Dakkak, Imad (author)
Alexion Pharmaceuticals
Green, Janet (author)
No affiliation available (private)
Haas, Christian Stefan (author)
Philipp University of Marburg
Román-Ortiz, Elena (author)
Hospital Universitario Doctor Peset
Cheong, Hae Il (author)
Seoul National University Hospital
Sartz, Lisa (author)
Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
Swinford, Rita (author)
University of Texas
Tomazos, Ioannis (author)
Alexion Pharmaceuticals
Miller, Benjamin (author)
Alexion Pharmaceuticals
Cataland, Spero (author)
Ohio State University
show less...
 (creator_code:org_t)
Elsevier BV, 2020
2020
English 11 s.
In: Kidney International Reports. - : Elsevier BV. - 2468-0249. ; 5:8, s. 1161-1171
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Introduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive and potentially life-threatening disease characterized by complement-mediated thrombotic microangiopathy. Patients with aHUS may experience fatigue, which can negatively impact their lives, but there is a knowledge gap regarding disease burden in these patients. Methods: In this longitudinal study, patients with aHUS from the Global aHUS Registry who completed patient-reported outcome assessments (Functional Assessment of Chronic Illness Therapy-Fatigue scale [FACIT-Fatigue], general health status, and work status) at ≥2 time points were assessed relative to treatment status: (i) never treated with eculizumab; (ii) on eculizumab at registry enrollment and continued therapy; and (iii) started eculizumab after registry enrollment. Results: Patients who started eculizumab after the baseline visit (n = 23) exhibited improvements in fatigue (nearly 75% achieved clinically meaningful improvement), improved general health status (55%), and 25% to 30% rate reduction in symptoms of fatigue, weakness, irritability, nausea/vomiting, and swelling at last follow-up. Among patients already on eculizumab at registry enrollment (n = 295) and those never treated (n = 233), these parameters changed minimally relative to the baseline. Emergency room visits and hospital admissions were similar between groups. The number of health care provider visits and work days missed were higher in patients who started eculizumab after registry enrollment. Conclusion: These real-world findings confirm the detrimental effects of aHUS on patients’ daily lives, including high levels of fatigue and impairments in general health status. The results suggest clinically meaningful improvement in fatigue, other patient-reported outcomes, and symptoms with eculizumab initiation after enrollment into the aHUS registry.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Keyword

aHUS
atypical hemolytic uremic syndrome
complement
FACIT-Fatigue
fatigue
patient-reported outcomes

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view